biotech

Amgen Gains Worldwide Rights to Biovitrum's Lead Candidate For Type 2 Diabetes

Filed in archive Corporate and Industrial News , Drugs, Vaccines and Therapeutics , Patents and Intellectual Property Rights on February 14, 2006

BlogPicture

In a revised, expanded agreement, Amgen receives exclusive worldwide rights to develop and commercialize Biovitrum's drug candidate for Type 2 diabetes and related metabolic Diseases. Previously, Amgen had exclusive rights to commercialize products only in North and South America, the European Union, Australia and New Zealand.

Biovitrum's lead compound, 11beta-HSD1 enzyme inhibitors, are currently under early clinical development.



Permalink: Amgen Gains Worldwide Rights to Biovitrum's Lead Candidate For Type 2 Diabetes

Tags: diabetes  amgen  biotech  type  rights  type+diabetes  biovitrum+lead  candidate+type 

Vote for Amgen Gains Worldwide Rights to Biovitrum's Lead Candidate For Type 2 Diabetes:

  • Currently 6.00/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 6.00 out of 1 vote(s) cast.
 
Share It
RSSrss
Google google
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Most Popular   Best of   Biotech Hubs and Facilities   Biotech/Science Blogs   Corporate and Industrial News   Diagnostics, Methodologies and Instrumentation   Did you know   Drugs, Vaccines and Therapeutics   Energy, Environment and Ecology   Food and Agriculture   Gene Therapy   Genomics, Proteomics and Bioinformatics   Information About   Meetings and Other Events   Microbiology   Misc   Nanomedicine   Other Biotechnology News   Patents and Intellectual Property Rights   Quick introduction   Stem Cells